ARTICLE | Clinical News
Corluxin mifepristone regulatory update
November 11, 2013 8:00 AM UTC
Corcept disclosed in its 3Q13 earnings that it submitted an MAA to EMA for Corluxin mifepristone to treat endogenous Cushing's syndrome. Corcept expects feedback from EMA in 1Q14. Corcept markets the ...